|
Post by liane on Mar 4, 2017 14:07:33 GMT -5
FYI everyone - you really don't need to copy lengthy stuff here. Just give a link. And if you're quoting a lengthy post, please edit it down to just the highlights. Thank You!
|
|
|
Post by sayhey24 on Mar 4, 2017 14:09:52 GMT -5
I politely ask the moderators to allow this thread to remain in All About MannKind because it is important for everyone to be able to see this information that they otherwise might not. The Federal Class Action lawsuit against Sanofi, Novo Nordisk and Eli Lilly was filed on 1/30/2017 on charges of colluding in insulin price fixing, among other things. The web of corruption that runs among these three companies is an intricate one. This thread is dedicated to the discussion on the Class Action filed against Sanofi, Novo Nordisk and Eli Lilly.... It would be really nice to see this all over the mainstream news !!! And if MNKD could somehow take advantage of this...IMO If Matt had a phone, maybe he has used it and already met with Bernie Sanders. I have sent the Senator links about afrezza and old interviews with Al after getting the FDA rejections. A nice spot on 60 minutes with Bernie announcing a price cut on afrezza wouldn't hurt. Having Bernie sponsoring a VA deal would also be nice.
|
|
|
Post by careful2invest on Mar 4, 2017 14:11:03 GMT -5
Perfect time for MNKD to differentiate themselves even more in the public eye and media in general by showing that not only were they (MNKD) not a part of it. MNKD can announce that they have lowered the price of AFREZZA. In doing so, MNKD can appear to be the hero humanitarians that not only charge less, but offer an alternative that can actually lower a users A1C at the same time, and oh yea, it's also inhaleable! If MNKD does not try to monopolize on this event, they are truly inept and I made a $200,000.00 plus dollar mistake in my investment. If this does not pan out, I'm going to have to change my screen name. Because clearly, I was not careful enough 2 invest! I feel that if they drastically lower their price in the midst of this that it would be *I can't think of a word I am feeling about it, but almost would be like saying it is already way too high and also they would be setting themselves up for a trap. If they lower it and then need to raise it legitimately, they potentially would face scrutiny. I don't think they need to lower the price. I do think that there could be an opportunity to draw positive attention however, but in what way and what form I have no idea. I respect your opinion, and thank you for posting this find, but in response to your post, The fact is that AFREZZA is basically not selling. When your product or service is not selling, from a marketing perspective, you must identify the problems... In part, it was insurance and spirometry in the beginning, MNKD has addressed those issues. What is it now? Partly still due to Label, lack of exposure and advertisement, Doctors reluctance to try it, (Docs receiving too much money from BP?) etc...etc But when current methods of sales are not working, one must think of an angle to gain that edge to sell your product. The ability to lower your price is probably the most effective, although I am not minimizing the importance of the aforementioned. Nowhere did I say a "drastic" reduction, simply just sell lower than your competition. Once you gain market acceptance, gradually raise your price to a point of fair, yet decent sustainable profit margins. If Afrezza works as good as reported by so many, with longterm benefits due to "time in range" etc, most patients would be willing to pay a little more for a better quality of life and even an extension of life! Once proven, Insurance companies would probably soon follow. I do not get MNKD's MO! And all the while, the pps gets slaughtered!!
|
|
|
Post by peppy on Mar 4, 2017 14:15:10 GMT -5
"If MannKind is approved of an ultra-rapid label, they are in a class of their own. No competition in that category that I know of..." Maybe, just maybe the FDA has made some gesture that has MNKD management thinking that this decision is coming sooner than later. I repeat, just maybe. I want to point out to the board, there is no ultra rapid insulin category. I believe the category needs to be created. Am I wrong?
|
|
|
Post by mango on Mar 4, 2017 14:25:27 GMT -5
There are some studies already currently going on with injectable insulins and CGM. Might be Dexcom's. What are the studies for? I would think MNKD could bring their own law suits if they are not included depending on what the studies are for. Nothing can beat monomer human insulin when properly dosed and I would be surprised if they can show non-inferiority. This is the Dexcom one I was thinking of, but now that I look at it, it started in 2014 and ended in May 2016. Was just updated on clinicaltrials.gov in 2017. Dr. Janet B. McGill was also involved, remember her from the Consensus Committee. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical TrialObjective To determine the effectiveness of CGM in adults with type 1 diabetes treated with insulin injections. Design, Setting, and Participants Randomized clinical trial conducted between October 2014 and May 2016 at 24 endocrinology practices in the United States that included 158 adults with type 1 diabetes who were using multiple daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%. Interventions Random assignment 2:1 to CGM (n = 105) or usual care (control group; n = 53). Main Outcomes and Measures Primary outcome measure was the difference in change in central-laboratory–measured HbA1c level from baseline to 24 weeks. There were 18 secondary or exploratory end points, of which 15 are reported in this article, including duration of hypoglycemia at less than 70 mg/dL, measured with CGM for 7 days at 12 and 24 weeks. Results Among the 158 randomized participants (mean age, 48 years [SD, 13]; 44% women; mean baseline HbA1c level, 8.6% [SD, 0.6%]; and median diabetes duration, 19 years [interquartile range, 10-31 years]), 155 (98%) completed the study. In the CGM group, 93% used CGM 6 d/wk or more in month 6. Mean HbA1c reduction from baseline was 1.1% at 12 weeks and 1.0% at 24 weeks in the CGM group and 0.5% and 0.4%, respectively, in the control group (repeated-measures model P < .001). At 24 weeks, the adjusted treatment-group difference in mean change in HbA1c level from baseline was –0.6% (95% CI, –0.8% to –0.3%; P < .001). Median duration of hypoglycemia at less than <70 mg/dL was 43 min/d (IQR, 27-69) in the CGM group vs 80 min/d (IQR, 36-111) in the control group (P = .002). Severe hypoglycemia events occurred in 2 participants in each group. Conclusions and Relevance Among adults with type 1 diabetes who used multiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decrease in HbA1c level during 24 weeks. Further research is needed to assess longer-term effectiveness, as well as clinical outcomes and adverse effects.this year. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial
jamanetwork.com/journals/jama/article-abstract/2598770clinicaltrials.gov/show/NCT02282397
|
|
|
Post by mango on Mar 4, 2017 14:27:29 GMT -5
It would be really nice to see this all over the mainstream news !!! And if MNKD could somehow take advantage of this...IMO If Matt had a phone, maybe he has used it and already met with Bernie Sanders. I have sent the Senator links about afrezza and old interviews with Al after getting the FDA rejections. A nice spot on 60 minutes with Bernie announcing a price cut on afrezza wouldn't hurt. Having Bernie sponsoring a VA deal would also be nice. Bernie is visiting my state today.
|
|
|
Post by peppy on Mar 4, 2017 14:29:37 GMT -5
If Matt had a phone, maybe he has used it and already met with Bernie Sanders. I have sent the Senator links about afrezza and old interviews with Al after getting the FDA rejections. A nice spot on 60 minutes with Bernie announcing a price cut on afrezza wouldn't hurt. Having Bernie sponsoring a VA deal would also be nice. Bernie is visiting my state today.Any chance you can slip him a dreamboat?
|
|
|
Post by kc on Mar 4, 2017 14:35:09 GMT -5
|
|
|
Post by mango on Mar 4, 2017 14:40:19 GMT -5
I feel that if they drastically lower their price in the midst of this that it would be *I can't think of a word I am feeling about it, but almost would be like saying it is already way too high and also they would be setting themselves up for a trap. If they lower it and then need to raise it legitimately, they potentially would face scrutiny. I don't think they need to lower the price. I do think that there could be an opportunity to draw positive attention however, but in what way and what form I have no idea. I respect your opinion, and thank you for posting this find, but in response to your post, The fact is that AFREZZA is basically not selling. When your product or service is not selling, from a marketing perspective, you must identify the problems... In part, it was insurance and spirometry in the beginning, MNKD has addressed those issues. What is it now? Partly still due to Label, lack of exposure and advertisement, Doctors reluctance to try it, (Docs receiving too much money from BP?) etc...etc But when current methods of sales are not working, one must think of an angle to gain that edge to sell your product. The ability to lower your price is probably the most effective, although I am not minimizing the importance of the aforementioned. Nowhere did I say a "drastic" reduction, simply just sell lower than your competition. Once you gain market acceptance, gradually raise your price to a point of fair, yet decent sustainable profit margins. If Afrezza works as good as reported by so many, with longterm benefits due to "time in range" etc, most patients would be willing to pay a little more for a better quality of life and even an extension of life! Once proven, Insurance companies would probably soon follow. I do not get MNKD's MO! And all the while, the pps gets slaughtered!! How much could they realistically lower it and still make a meaningful profit? After reading the full details of the lawsuit filings I am afraid that it is obvious who controls what the majority of patients are prescribed. There are not any FDA documented post-approval adverse reactions nor are there any documented cases of lung cancer or any other pulmonary disease. The fact is the endo leaders that design things like consensus statements on recommended protocols cater to the whims of their pharmaceutical backers, and the medical community refers to these for guideance. Without properly written protocols by these people clinicians will not be inclinced to change their habits unless influenced outside of the contexts of such official positions. MannKind needs to target family med and acute care clinics, IMO, and ditch the endos.
|
|
|
Post by mango on Mar 4, 2017 14:43:26 GMT -5
Bernie is visiting my state today. Any chance you can slip him a dreamboat? I'll see what I can do when he comes over for the BBQ and some RLS
|
|
|
Post by derek2 on Mar 4, 2017 14:45:36 GMT -5
The article goes into that. It seems like the article is bashing the plaintiffs and attorneys, no? Or maybe I am missing something? How dare I post it. I usually don't get involved in your posts. I think I should continue that. You'll be happier and I will be too.
|
|
|
Post by mango on Mar 4, 2017 14:49:52 GMT -5
It seems like the article is bashing the plaintiffs and attorneys, no? Or maybe I am missing something? How dare I post it. I usually don't get involved in your posts. I think I should continue that. You'll be happier and I will be too. I was just wondering dude, relax. I can't really decipher what the author is trying to highlight.
|
|
|
Post by mnkdfann on Mar 4, 2017 14:55:13 GMT -5
nothing to see here folks. The end result will be each of them paying few hundred million $ in fines and the statement will be "Paid fines and it doesnt mean that there was any wrong doing" Business as usual. Same game different players. I tend to agree. FYI, this isn't the first class action / RICO lawsuit brought by Hagens Berman Sobol Shapiro LLP against Sanofi. Note that the last one was tossed. www.law360.com/articles/847507/high-court-won-t-hear-rico-causation-suit-over-sanofi-drugI'm not a lawyer, but I think this class action has way less merit than that earlier one.
|
|
|
Post by mango on Mar 4, 2017 15:03:16 GMT -5
nothing to see here folks. The end result will be each of them paying few hundred million $ in fines and the statement will be "Paid fines and it doesnt mean that there was any wrong doing" Business as usual. Same game different players. I tend to agree. FYI, this isn't the first class action / RICO lawsuit brought by Hagens Berman Sobol Shapiro LLP against Sanofi. Note that the last one was tossed. www.law360.com/articles/847507/high-court-won-t-hear-rico-causation-suit-over-sanofi-drugI'm not a lawyer, but I think this class action has way less merit than that earlier one.Did you read the filing? If not, what are you basing your thinking off of? I just read about that case and this current one blows the lid off compared to the one you mentioned.
|
|
|
Post by kc on Mar 4, 2017 15:14:55 GMT -5
|
|